IP Library Granted Patent US 9,783,552
Granted Patent B2
US 9,783,552 · App. 15/103,148 · Granted Oct 10, 2017

Soluble guanylate cyclase activators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,783,552
App. No.
15/103,148
Granted
Oct 10, 2017
Kind
B2
Abstract

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Claims (186)

1. A compound having structural Formula I:

or a pharmaceutically acceptable salt thereof wherein:

X 1 and X 2 are each independently CR or N;

R is —H, halo or cyclopropyl;

R 1 is —H or —C 1-6 alkyl unsubstituted or substituted with one to three of —F;

R 2 is (a) —C 1-6 alkyl unsubstituted or substituted with

(i) one to six of —F,

(ii) —C 3-6 cycloalkyl unsubstituted or substituted with one to three of —F or

(iii) phenyl unsubstituted or independently substituted at each occurrence with one to three of halo, —CN, —CH 3 or —OCH 3 ,

 (b) —C 3-6 cycloalkyl unsubstituted or substituted with one to three of —F, or

 (c) phenyl unsubstituted or independently substituted at each occurrence with one to three of halo, —CN, —CH 3 or —OCH 3 ;

R 2a is —H or —C 1-3 alkyl unsubstituted or substituted with one to three of —F;

R 2b is —H or —C 1-3 alkyl unsubstituted or substituted with one to three of —F;

or R 2b is —H and R 2 and R 2a are joined together with the carbon to which they are both attached to represent

(a) —C 3-6 cycloalkyl unsubstituted or substituted with one to three of —F, or

(b) a 4 to 6 membered heterocycle comprised of carbons and one or two heteroatoms independently selected from N, O or S, wherein the heterocycle is unsubstituted or independently substituted at each occurrence with one to three of halo, —CN, —CH 3 or —OCH 3 ;

R 3 is —C 1-6 alkyl or —C 3-6 cycloalkyl;

R 4 is (a) —C 1-6 alkyl,

(b) —OC 1-6 alkyl

(c) —C 2-6 alkynyl,

(d) —C 3-6 cycloalkyl,

(e) —COO—C 1-6 alkyl

(f) —NHR a ,

(g) —NH—C(O)—R a ,

(h) —C(O)NHR a ,

(i) —CN,

(j) phenyl unsubstituted or substituted with one to three substituents independently selected at each occurrence from halo, —C 1-6 alkyl, —OC 1-6 alkyl, —OH or —CN; or

(k) phenyl substituted with a 5 or 6 membered heteroaryl comprised of carbon atoms, one to three of N, and zero or one of O, wherein the heteroaryl is unsubstituted or substituted with —C 1-3 alkyl;

R a is (a) —H, (b) —C 1-6 alkyl unsubstituted or substituted with one or more substituents independently selected from —OH, one to three of —F,

(c) —C 1-3 alkyl-C 3-6 cycloalkyl, (d) —C 3-6 cycloalkyl, or (e) a 5 or 6 membered heteroaryl comprised of carbon atoms and one to three heteroatoms independently selected from N, O and S, wherein the heteroaryl is unsubstituted or substituted with —C 1-3 alkyl;

R 5 is —H, —OR 6 or —NHR 6 ; and

R 6 is —H, —C 1-6 alkyl or —C 3-6 cycloalkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein: X 1 and X 2 are each independently CH or N,

R 1 is —H or —C 1-3 alkyl;

R 3 is —C 1-6 alkyl or —C 3-6 cycloalkyl; and

R 5 is —H, —OH or —NH 2 .

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein:

X 1 and X 2 are each independently CH or N,

R 1 is —H or —C 1-3 alkyl;

R 2 is (a) —C 1-6 alkyl substituted with

(i) one to six of —F,

(ii) —C 3-6 cycloalkyl substituted with one to three of —F or

(iii) phenyl substituted with one to three of —F,

 (b) —C 3-6 cycloalkyl substituted with one to three of —F, or

 (c) phenyl substituted with one to three of —F;

R 3 is —C 1-6 alkyl or —C 3-6 cycloalkyl;

R 4 is (a) —C 1-6 alkyl,

(b) —OC 1-6 alkyl

(c) —C 2-3 alkynyl,

(d) —C 3-6 cycloalkyl,

(e) —COO—C 1-3 alkyl,

(f) —NHR a ,

(g) —NH—C(O)—R a ,

(h) —C(O)NHR a ,

(i) —CN,

(j) phenyl unsubstituted or substituted with one to three substituents independently selected at each occurrence from halo, —C 1-3 alkyl, —OC 1-3 alkyl, —OH or —CN; or

(k) phenyl substituted with a 5 or 6 membered heteroaryl comprised of carbon atoms, one to three of N, and zero or one of O, wherein the heteroaryl is unsubstituted or substituted with —C 1-3 alkyl;

R a is (a) —H,

(b) —C 1-6 alkyl unsubstituted or substituted with one or more substituents independently selected from —OH and one to three of —F,

(c) —C 1-3 alkyl-C 3-6 cycloalkyl,

(d) —C 3-6 cycloalkyl, or

(e) 5 or 6 membered heteroaryl comprised of carbon atoms and one to three of N, wherein the heteroaryl is unsubstituted or substituted with —C 1-3 alkyl; and

R 5 is —H, —OH or —NH 2 .

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 2 is

(a) —C 1-6 alkyl substituted with

(i) one to six of —F,

(ii) —C 3-6 cycloalkyl substituted with one to three of —F, or

(iii) phenyl substituted with one to three of —F,

(b) —C 3-6 cycloalkyl substituted with one to three of —F, or

(c) phenyl substituted with one to three of —F.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein is R 3 is —C 1-3 alkyl or cyclopropyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein is R 4 is

(a) —C 1-4 alkyl,

(b) —OC 1-4 alkyl,

(c) —C 2-3 alkynyl,

(d) —C 3-6 cycloalkyl,

(e) —COO—C 1-3 alkyl

(f) —NHR a ,

(g) —NH—C(O)—R a ,

(h) —C(O)NHR a ,

(i) —CN,

(j) phenyl unsubstituted or substituted with one to three substituents independently selected at each occurrence from —F, —Br, —C 1-3 alkyl, —OC 1-3 alkyl, —OH or —CN; or

(k) phenyl substituted with pyridyl, oxadiazolyl or pyrazolyl.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R a is (a) —H, (b) —C 1-4 alkyl unsubstituted or substituted with one or more substituents independently selected from —OH and one to three of —F, (c) —CH 2 —C 3-6 cycloalkyl, (d) —C 3-6 cycloalkyl, or (e) a heteroaryl which is pyridyl or pyrazolyl, wherein the heteroaryl is unsubstituted or substituted with —C 1-3 alkyl.

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 1 is —H, —CH 3 , —CD 3 , —CH 2 CH 3 or -CD 2 CD 3 .

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 5 is —NH 2 .

10. The compound of claim 1 , having the structural Formula Ia or a pharmaceutically acceptable salt thereof:

11. The compound of claim 1 , having the structural Formula Ib or a pharmaceutically acceptable salt thereof:

12. The compound of claim 1 , which is:

4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(1-methyl-6-(4,4,4-trifluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(1-methyl-6-(3,3,3-trifluoropropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(6-((3,3-difluorocyclobutyl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(6-(2,3-difluorobenzyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(1-ethyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-methyl-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-bromophenyl)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(1-methyl-6-(3,3,3-trifluoropropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5,5-dimethyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(3-methoxyphenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(3-fluoro-4-methoxyphenyl)-5-methyl-2-(1-methyl-6-(4,4,4-trifluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(3-fluoro-4-methoxyphenyl)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-cyclopropyl-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-cyclohexyl-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(1-ethyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(1-ethyl-6-(4,4,4-trifluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-ethynyl-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-ethynyl-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-ethyl-5-ethynyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-cyclopropyl-5-ethynyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-butyl-5-cyclopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

Ethyl 4-amino-5-cyclopropyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxylate;

Ethyl 4-amino-5-cyclopropyl-2-(1-methyl-6-(4,4,4-trifluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxylate;

4-Amino-N,5-dicyclopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-cyclopropyl-N-ethyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N,5-dicyclopropyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-ethyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-isopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5N-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-ethyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-isopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N,5-dicyclopropyl-2-(1-ethyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-ethyl-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-2-(6-(2,3-difluorobenzyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-cyclopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-N-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-amino-5-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-(4-hydroxyphenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(3-hydroxyphenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

5-(4-(1,3,4-Oxadiazol-2-yl)phenyl)-4-amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-(4-Amino-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile;

5-(4-Fluorophenyl)-4-hydroxy-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile;

4,5-Diamino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

N-(4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)picolinamide;

N-(4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-cyclopropylacetamide;

N-(4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)cyclopropanecarboxamide;

4-Amino-5-((cyclopropylmethyl)amino)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(isopropylamino)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methoxy-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-5-trideuteriomethoxy-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(3-chloro-1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(3-cyclopropyl-6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2′-(3,3,4,4,4-pentafluorobutyl)-5-phenyl-7′-trideuteriomethyl-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5,7′-dimethyl-2′-(3,3,4,4,4-pentafluorobutyl)-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5,7′-dimethyl-2′-(3,3,4,4,4-pentafluorobutyl)-5-phenyl-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5,5,7′-trimethyl-2′-(3,3,4,4,4-pentafluorobutyl)-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-2′-(2,3-difluorobenzyl)-5,7′-dimethyl-5-phenyl-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5-methyl-2′-(3,3,4,4,4-pentafluorobutyl)-5-phenyl-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-2-(5-(2,3-difluorobenzyl)-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-cyclopropyl-5-(4-fluorophenyl)-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-chlorophenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-methoxyphenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluoro-3-methoxyphenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-chloro-2-fluorophenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

or a pharmaceutically acceptable salt of each of the foregoing compounds.

13. The compound of claim 1 , which is:

4-Amino-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-methyl-2-(1-methyl-6-(3,3,3-trifluoropropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(6-(2,3-difluorobenzyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-(4-fluorophenyl)-5-methyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-2-(1-ethyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5-methyl-5-phenyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5,5-dimethyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-N,5-dicyclopropyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-methyl-2-(1-methyl-6-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-N-cyclopropyl-5-methyl-2-(6-(3,3,4,4,4-pentafluorobutyl)-1-trideuteriomethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide;

4-Amino-5-(4-fluorophenyl)-5,7′-dimethyl-2′-(3,3,4,4,4-pentafluorobutyl)-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5,7′-dimethyl-2′-(3,3,4,4,4-pentafluorobutyl)-5-phenyl-5H,7′H-[2,4′-bipyrrolo[2,3-d]pyrimidin]-6(7H)-one;

4-Amino-5-(4-fluorophenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-cyclopropyl-5-(4-fluorophenyl)-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-methoxyphenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

4-Amino-5-(4-chloro-2-fluorophenyl)-5-methyl-2-(5-(3,3,4,4,4-pentafluorobutyl-3-trideuteriomethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one;

or a pharmaceutically acceptable salt of each of the foregoing compounds.

14. A method for activating soluble guanylate cyclase comprising the step of administering an amount efficacious therefore of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

15. A method for the treatment of hypertension comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

16. A method for the treatment of heart failure comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

17. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 further comprising one or more additional active agents selected from an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a neutral endopeptidase inhibitor, an aldosterone antagonist, a renin inhibitor, an endothelin receptors antagonist, an aldosterone synthase inhibitor, a phosphodiesterase-5 inhibitor, a vasodilator, a calcium channel blocker, a potassium channel activator, a diuretic, a sympatholitic, a beta-adrenergic blocking drug, an alpha adrenergic blocking drug, a central alpha adrenergic agonist, a peripheral vasodilator, a lipid lowering agent or a metabolic altering agent.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2016
From: HAN, XIAOQING; WHITEHEAD, ALAN; RAGHAVAN, SUBHAREKHA; CERNAK, TIMOTHY A.; DREHER, SPENCER; GROEPER, JONATHAN; GUO, JIAN; ZHANG, YONG
To: MERCK SHARP & DOHME CORP.
Reel/Frame 039037/0443 →